High uric acid exacerbates nonalcoholic steatohepatitis through NLRP3 inflammasome and gasdermin D-mediated pyroptosis
Journal of Biological Chemistry · 2025
DOI: 10.1016/j.jbc.2025.110249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Zixin Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Non-alcoholic Fatty Liver Disease, Pyroptosis, Phosphate-Binding Proteins. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Zhejiang University, Key Research and Development Program of Zhejiang Province.
Abstract (Originalsprache)
Hyperuricemia is independently associated with an increased risk of nonalcoholic steatohepatitis (NASH), but the underlying mechanisms responsible for this association remain unclear. We first analyzed the association between intrahepatic UA levels and gasdermin D (GSDMD)-mediated pyroptosis in vivo and in vitro. We subsequently generated hepatic-specific glucose transporter 9 (GLUT9)-knockout mice and GSDMD knockout (GSDMD-/-) mice to explore the role of intrahepatic UA in GSDMD-induced pyroptosis in NASH. We found that high intrahepatic UA levels were positively related to GSDMD-mediated pyroptosis in NASH mice. The inhibition of hepatic UA production by allopurinol alleviated hepatic inflammation and GSDMD-mediated pyroptosis in NASH mice. Hepatic-specific knockout of Glut9 significantly decreased intrahepatic UA levels, attenuated NOD-like receptor family pyrin domain containing 3 (NLRP3)-Caspase-1-GSDMD-mediated pyroptosis in hepatocytes, and ameliorated hepatic inflammation and fibrosis in different mouse models of NASH. Further experiments revealed that inhibiting the NLRP3/Caspase-1/GSDMD pathway obviously blocked UA-induced pyroptosis and inflammation in hepatocytes. Additionally, GSDMD deficiency markedly reversed hepatic inflammation and fibrosis in NASH mice. In conclusion, our results showed that high UA could induce NLRP3-Caspase1-GSDMD-mediated pyroptosis, thereby aggravating NASH in mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Zhejiang Provincial Key Laboratory of Laboratory Animals and Safety Research, Hangzhou Medical College, Hangzhou, China. Electronic address: shiqiaojuan@163.com.
- Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Electronic address: zyyyych@zju.edu.cn.
- Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Electronic address: xiaofu@zju.edu.cn.
Förderung
- National Natural Science Foundation of China
- Zhejiang University
- Key Research and Development Program of Zhejiang Province
Zitieren
APA
Xu, Z., Tang, C., Song, X., Liu, Z., Zhou, J., Shi, Q., Yu, C., & Xu, C. (2025). High uric acid exacerbates nonalcoholic steatohepatitis through NLRP3 inflammasome and gasdermin D-mediated pyroptosis. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.110249
Vancouver
Xu Z, Tang C, Song X, Liu Z, Zhou J, Shi Q, et al. High uric acid exacerbates nonalcoholic steatohepatitis through NLRP3 inflammasome and gasdermin D-mediated pyroptosis. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.110249
BibTeX
@article{Xu2025,
author = {Xu, Zixin and Tang, Chenxi and Song, Xin and Liu, Zhening and Zhou, Jiaming and Shi, Qiaojuan and Yu, Chaohui and Xu, Chengfu},
title = {High uric acid exacerbates nonalcoholic steatohepatitis through NLRP3 inflammasome and gasdermin D-mediated pyroptosis},
journal = {Journal of Biological Chemistry},
year = {2025},
doi = {10.1016/j.jbc.2025.110249}
}
EUVIMED